Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
0.909
+0.035 (3.96%)
Jan 14, 2025, 4:00 PM EST - Market closed
Adicet Bio Employees
Adicet Bio had 143 employees as of December 31, 2023. The number of employees increased by 11 or 8.33% compared to the previous year.
Employees
143
Change (1Y)
11
Growth (1Y)
8.33%
Revenue / Employee
n/a
Profits / Employee
-$824,364
Market Cap
74.92M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 143 | 11 | 8.33% |
| Dec 31, 2022 | 132 | 46 | 53.49% |
| Dec 31, 2021 | 86 | 4 | 4.88% |
| Dec 31, 2020 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
ACET News
- 6 days ago - Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Business Wire
- 14 days ago - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 26 days ago - Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
- 27 days ago - Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - Business Wire
- 2 months ago - Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
- 2 months ago - Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Business Wire
- 2 months ago - Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire
- 2 months ago - Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates - Business Wire